Can a common diabetes pill help transplant patients?

NCT ID NCT07228195

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests whether empagliflozin (Jardiance), a drug used for type 2 diabetes, can improve blood sugar control in people who have had an islet transplant and still have partial islet function. About 40 adults will receive either a placebo, 10 mg, or 25 mg of empagliflozin daily for 3 months. The main goal is to see if the drug increases the time their blood sugar stays in a healthy range.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance) 10 mg or 25 mg oral tablet
What this could lead to: If it works, this could help islet transplant recipients achieve better blood sugar control and reduce their insulin doses.
What could go wrong: This is a small, early pilot study with only 40 participants. The drug is already approved for type 2 diabetes but not specifically for this use, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES PARTIAL ISLET FUNCTION TPIAT

Contacts and locations

Locations

University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.